IN2014CN02527A - - Google Patents

Download PDF

Info

Publication number
IN2014CN02527A
IN2014CN02527A IN2527CHN2014A IN2014CN02527A IN 2014CN02527 A IN2014CN02527 A IN 2014CN02527A IN 2527CHN2014 A IN2527CHN2014 A IN 2527CHN2014A IN 2014CN02527 A IN2014CN02527 A IN 2014CN02527A
Authority
IN
India
Prior art keywords
methods
etanercept
compositions
stabilized
administration
Prior art date
Application number
Other languages
English (en)
Inventor
Mark Manning
Brian Murphy
Original Assignee
Coherus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coherus Biosciences Inc filed Critical Coherus Biosciences Inc
Publication of IN2014CN02527A publication Critical patent/IN2014CN02527A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
IN2527CHN2014 2011-10-18 2012-10-18 IN2014CN02527A (OSRAM)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161548518P 2011-10-18 2011-10-18
US201261669480P 2012-07-09 2012-07-09
PCT/US2012/060738 WO2013059405A1 (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with amino acids

Publications (1)

Publication Number Publication Date
IN2014CN02527A true IN2014CN02527A (OSRAM) 2015-06-26

Family

ID=48136153

Family Applications (3)

Application Number Title Priority Date Filing Date
IN2591CHN2014 IN2014CN02591A (OSRAM) 2011-10-18 2012-10-18
IN2592CHN2014 IN2014CN02592A (OSRAM) 2011-10-18 2012-10-18
IN2527CHN2014 IN2014CN02527A (OSRAM) 2011-10-18 2012-10-18

Family Applications Before (2)

Application Number Title Priority Date Filing Date
IN2591CHN2014 IN2014CN02591A (OSRAM) 2011-10-18 2012-10-18
IN2592CHN2014 IN2014CN02592A (OSRAM) 2011-10-18 2012-10-18

Country Status (28)

Country Link
US (21) US10293049B2 (OSRAM)
EP (6) EP2768531A4 (OSRAM)
JP (6) JP6104922B2 (OSRAM)
KR (7) KR20140091707A (OSRAM)
CN (6) CN104010657A (OSRAM)
AR (6) AR088383A1 (OSRAM)
AU (6) AU2012326080B2 (OSRAM)
BR (6) BR112014009087A2 (OSRAM)
CA (6) CA2851628A1 (OSRAM)
CY (1) CY1121843T1 (OSRAM)
DK (1) DK2768525T3 (OSRAM)
EA (6) EA025663B1 (OSRAM)
ES (1) ES2734070T3 (OSRAM)
HK (3) HK1200718A1 (OSRAM)
HR (1) HRP20191215T1 (OSRAM)
HU (1) HUE045624T2 (OSRAM)
IL (6) IL231825A0 (OSRAM)
IN (3) IN2014CN02591A (OSRAM)
LT (1) LT2768525T (OSRAM)
MX (7) MX2014004734A (OSRAM)
PL (1) PL2768525T3 (OSRAM)
PT (1) PT2768525T (OSRAM)
RS (1) RS59179B1 (OSRAM)
SG (6) SG11201401517VA (OSRAM)
SI (1) SI2768525T1 (OSRAM)
SM (1) SMT201900422T1 (OSRAM)
TW (6) TWI619504B (OSRAM)
WO (6) WO2013059406A1 (OSRAM)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101217979A (zh) 2005-06-14 2008-07-09 安姆根有限公司 自缓冲蛋白制剂
US10485869B2 (en) 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
KR20140091707A (ko) * 2011-10-18 2014-07-22 코히러스 바이오사이언시즈, 인코포레이티드 크실리톨로 안정화된 에타너셉트 제형
KR20150030704A (ko) * 2012-07-09 2015-03-20 코히러스 바이오사이언시즈, 인코포레이티드 육안으로 보이지 않는 입자의 현저한 감소를 나타내는 에타너셉트 제형
PT2895188T (pt) * 2012-09-11 2018-02-08 Coherus Biosciences Inc Etanercept dobrado corretamente de pureza elevada e rendimento excelente
AU2014261477A1 (en) * 2013-05-02 2015-11-19 Mabxience, S.A. Alternative formulations for TNFR: Fc fusion polypeptides
WO2015056613A1 (ja) * 2013-10-15 2015-04-23 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 安定化されたポリペプチド水性製剤
RS62419B1 (sr) * 2013-10-24 2021-10-29 Astrazeneca Ab Stabilne vodene formulacije antitela
WO2015080513A1 (en) * 2013-11-29 2015-06-04 Hanwha Chemical Corporation A liquid formulation of a fusion protein comprising tnfr and fc region
IS3008B (is) 2014-05-14 2018-12-15 Calor ehf Stöðgandi lausnir fyrir prótín og peptíð
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
EP3207936B1 (en) * 2014-11-18 2021-04-21 Shionogi & Co., Ltd. Stable peptide composition
JP6885875B2 (ja) 2014-12-22 2021-06-16 アレス トレーディング ソシエテ アノニム 液体医薬組成物
US20180256717A1 (en) * 2014-12-23 2018-09-13 Drug Discovery Laboratory As Protein compositions and use thereof
WO2016108569A1 (ko) * 2014-12-31 2016-07-07 주식회사 엘지생명과학 목적하는 함량으로 불순물을 포함하는 tnfr-fc 융합 단백질의 제조방법
CN104694355B (zh) * 2015-03-20 2016-09-28 吉林大学 葛根护肝保健酒及其制备方法
MX389818B (es) * 2015-08-13 2025-03-20 Landsteiner Scient S A De C V Composicion de estabilidad mejorada de etanercept.
JP5938762B1 (ja) * 2015-09-01 2016-06-22 日揮株式会社 マイクロカプセル製剤及びその製造方法
CN105748414A (zh) * 2016-03-02 2016-07-13 张光泉 抗感染米卡芬净冻干组合物及其制备方法
WO2017179683A1 (ja) * 2016-04-15 2017-10-19 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 ミカファンギンの安定化された医薬組成物
SG11201903521XA (en) * 2016-10-21 2019-05-30 Amgen Inc Pharmaceutical formulations and methods of making the same
WO2018080196A2 (ko) 2016-10-28 2018-05-03 (주)셀트리온 안정한 약제학적 제제
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
MX2017013995A (es) * 2017-10-31 2019-05-01 Probiomed S A De C V Formulacion farmaceutica estable de una proteina de fusion.
KR20200093628A (ko) * 2017-11-30 2020-08-05 바이오-테라 솔루션즈 리미티드 Il-6 관련 질병을 치료하는 인간화항체의 액체 제제
AU2018388301B2 (en) * 2017-12-22 2022-02-17 Samsung Bioepis Co., Ltd. Liquid composition comprising VEGF antagonist
CA3042126A1 (en) 2018-05-03 2019-11-03 Michael A. Portman Methods of treating kawasaki disease
CN111228225B (zh) * 2018-11-28 2022-08-26 鲁南制药集团股份有限公司 一种重组人肿瘤坏死因子受体-Fc融合蛋白冻干制剂
GB201911461D0 (en) * 2019-08-09 2019-09-25 Arecor Ltd Novel composition
JP2023502777A (ja) * 2019-11-26 2023-01-25 コメラ ライフ サイエンシズ，インコーポレイテッド バイオポリマー製剤のための賦形剤化合物
MX2023009614A (es) 2021-02-17 2023-08-24 Arecor Ltd Composicion acuosa de una construccion de proteina modificada geneticamente que comprende un dominio fc.
CN114788809B (zh) * 2022-01-25 2023-04-14 江苏广承药业有限公司 一种氯雷他定液体制剂

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
EP0620739A4 (en) 1992-09-15 1997-01-15 Immunex Corp Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists.
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5656730A (en) 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
US6677326B2 (en) * 1999-03-15 2004-01-13 Arakis, Ltd. Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
AU4363200A (en) 1999-04-19 2000-11-02 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical desorders
WO2001058473A1 (en) 2000-02-10 2001-08-16 Wyeth Method of treating or inhibiting cellular injury or cell death
WO2002013860A1 (en) 2000-08-11 2002-02-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing preparations
WO2003102013A2 (en) * 2001-02-23 2003-12-11 Gonzalez-Villasenor Lucia Iren Methods and compositions for production of recombinant peptides
ATE402716T1 (de) 2002-02-27 2008-08-15 Immunex Corp Stabilisierte tnfr-fc formulierung mit arginin
ES2304602T3 (es) * 2003-02-28 2008-10-16 Ares Trading S.A. Formulaciones liquidas de la proteina de union al factor de necrosis tumoral tbp-1.
US20060177444A1 (en) 2003-03-20 2006-08-10 Tatsuo Horizoe Concomitant drug as therapeutic agent for inflammatory bowel disease
RU2006101216A (ru) 2003-08-01 2007-07-20 Амген Инк. (US) Кристаллические полипептиды 2 фактора некроза опухолей
AP2287A (en) 2003-10-14 2011-10-31 Intermune Inc Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication.
JP5554466B2 (ja) 2004-03-01 2014-07-23 味の素株式会社 抗ヒトＴＮＦ−α抗体活性低下抑制剤
JP2007525984A (ja) 2004-03-05 2007-09-13 ディーエスエム アイピー アセッツ ビー．ブイ． 連続的灌流および交互接線流による細胞培養の方法
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
JP5339901B2 (ja) 2005-05-10 2013-11-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド 炎症傷害の処置および評価
KR101367544B1 (ko) * 2005-06-10 2014-02-26 추가이 세이야쿠 가부시키가이샤 메글루민을 함유하는 단백질 제제의 안정화제, 및 그의이용
CN101217979A (zh) * 2005-06-14 2008-07-09 安姆根有限公司 自缓冲蛋白制剂
EP1962886B2 (en) 2005-12-20 2022-02-23 Bristol-Myers Squibb Company Stable protein formulations
CA2634131C (en) 2005-12-21 2014-02-11 Wyeth Protein formulations with reduced viscosity and uses thereof
EP1988922A4 (en) 2006-02-03 2010-06-02 Medimmune Llc PROTEIN FORMULATIONS
US7951918B2 (en) * 2006-03-17 2011-05-31 Biogen Idec Ma Inc. Stabilized polypeptide compositions
EP1996076A2 (en) 2006-03-21 2008-12-03 Eugen Oetringer Devices for and methods of analyzing a physiological condition of a physiological subject based on a workload related property
EP2021030A2 (en) 2006-04-21 2009-02-11 Amgen, Inc. Buffering agents for biopharmaceutical formulations
CN101627117B (zh) * 2006-08-01 2013-10-30 奇尼塔二有限责任公司 医药制造方法
AU2007307107B2 (en) * 2006-10-06 2011-11-03 Amgen Inc. Stable antibody formulations
MX2009003982A (es) * 2006-10-20 2009-04-27 Amgen Inc Formulaciones de polipeptido estables.
JP5401319B2 (ja) 2006-11-03 2014-01-29 ワイス・エルエルシー 細胞培養における解糖阻害物質
AU2007338791B2 (en) 2006-12-21 2014-03-13 Amgen Inc Stable buffered formulations containing polypeptides
DK2115126T3 (en) 2007-03-02 2015-05-04 Wyeth Llc Use of copper and glutamate in cell culture for the preparation of polypeptides
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
US20080311119A1 (en) * 2007-06-14 2008-12-18 Biogen Idec Ma Inc. Antibody formulations
CN104645329A (zh) 2007-11-30 2015-05-27 Abbvie公司 蛋白制剂及其制备方法
MX2010007728A (es) * 2008-01-15 2010-12-21 Abbott Gmbh & Co Kg Composiciones proteinicas en polvo y metodos para elaborar las mismas.
EP2615112A3 (en) 2008-02-29 2013-08-21 Biogen Idec MA Inc. Purified immunoglobulin fusion proteins and methods of their purification
WO2011015926A1 (en) 2009-08-03 2011-02-10 Avesthagen Limited A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein
CN102498206A (zh) 2009-08-11 2012-06-13 弗·哈夫曼-拉罗切有限公司 在无谷氨酰胺的细胞培养基中的蛋白质生产
US20120208986A1 (en) 2009-10-20 2012-08-16 Wenger Marc D Use of mixed mode chromatography for the capture and purification of basic antibody products
WO2011079308A2 (en) * 2009-12-23 2011-06-30 Emergent Product Development Seattle, Llc Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
PT2563904E (pt) 2010-04-26 2015-05-12 Novartis Ag Meio de cultura de células aperfeiçoado
EP2568960B1 (en) * 2010-05-10 2018-06-06 Intas Pharmaceuticals Ltd. Liquid formulation of polypeptides containing an fc domain of an immunoglobulin
WO2012013980A1 (en) * 2010-07-30 2012-02-02 Arecor Limited Stabilized aqueous antibody compositions
CA2807607A1 (en) 2010-08-20 2012-02-23 Wyeth Llc Cell culture of growth factor-free adapted cells
EP2611904A2 (en) 2010-08-31 2013-07-10 Friesland Brands B.V. Culture medium for eukaryotic cells
MX344268B (es) 2010-10-11 2016-12-09 Abbvie Inc * Proceso para purificacion de proteinas.
AU2012244764B2 (en) 2011-04-20 2016-10-13 Sandoz Ag Stable pharmaceutical liquid formulations of the fusion protein TNFR:Fc
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
WO2013003731A2 (en) 2011-06-29 2013-01-03 Insite Vision Incorporated Methods of treating recurrent meibomian glands disorder and thereby decreasing the frequency of recurrence
KR102061355B1 (ko) * 2011-07-01 2019-12-31 바이오젠 엠에이 인코포레이티드 아르기닌-없는 tnfr : fc-융합 폴리펩티드 조성물 및 이용 방법
ES2788132T3 (es) 2011-07-01 2020-10-20 Amgen Inc Cultivo de células de mamífero
US9781540B2 (en) * 2011-07-07 2017-10-03 Qualcomm Incorporated Application relevance determination based on social context
CA2840951A1 (en) 2011-07-08 2013-01-17 Merck Sharp & Dohme Corp. Methods for purifying fc-fusion protein
KR101454316B1 (ko) 2011-08-17 2014-10-27 한화케미칼 주식회사 활성형 ＴＮＦＲ-Ｆｃ 융합 단백질을 제조하는 방법
KR20140091707A (ko) * 2011-10-18 2014-07-22 코히러스 바이오사이언시즈, 인코포레이티드 크실리톨로 안정화된 에타너셉트 제형
PT2895188T (pt) 2012-09-11 2018-02-08 Coherus Biosciences Inc Etanercept dobrado corretamente de pureza elevada e rendimento excelente

Also Published As

Publication number Publication date
IL231825A0 (en) 2014-05-28
EP2768854A1 (en) 2014-08-27
EP2768533A1 (en) 2014-08-27
AR088382A1 (es) 2014-05-28
EP2768525A1 (en) 2014-08-27
SG11201401567YA (en) 2014-07-30
TWI644681B (zh) 2018-12-21
EA025267B1 (ru) 2016-12-30
CA2851651A1 (en) 2013-04-25
WO2013059407A1 (en) 2013-04-25
US11135267B2 (en) 2021-10-05
WO2013059412A1 (en) 2013-04-25
TW201325608A (zh) 2013-07-01
DK2768525T3 (da) 2019-07-22
KR20140079491A (ko) 2014-06-26
US9801942B2 (en) 2017-10-31
BR112014009146A2 (pt) 2017-06-13
AU2012326084B2 (en) 2016-12-15
EA201490804A1 (ru) 2014-09-30
HK1200721A1 (en) 2015-08-14
HK1200722A1 (en) 2015-08-14
CY1121843T1 (el) 2020-07-31
TW201325611A (zh) 2013-07-01
US9770510B2 (en) 2017-09-26
EA025663B1 (ru) 2017-01-30
JP6199298B2 (ja) 2017-09-20
CA2851642A1 (en) 2013-04-25
US9943601B2 (en) 2018-04-17
SMT201900422T1 (it) 2019-09-09
MX2019009176A (es) 2019-10-07
US10987405B2 (en) 2021-04-27
CA2851628A1 (en) 2013-04-25
EP2768532A1 (en) 2014-08-27
AU2012326168A1 (en) 2014-04-24
JP2014530256A (ja) 2014-11-17
US20190290768A1 (en) 2019-09-26
BR112014009073A2 (pt) 2017-05-09
IL231827A0 (en) 2014-05-28
AU2012326171B2 (en) 2017-03-09
AU2012326082B2 (en) 2016-12-15
SG11201401517VA (en) 2014-09-26
EA201490802A1 (ru) 2014-08-29
HRP20191215T1 (hr) 2019-10-04
KR20140083037A (ko) 2014-07-03
EP2768531A1 (en) 2014-08-27
TW201325607A (zh) 2013-07-01
MX2014004726A (es) 2015-05-15
KR20140097184A (ko) 2014-08-06
EP2768525B1 (en) 2019-06-19
KR20200008021A (ko) 2020-01-22
EA201490801A1 (ru) 2014-09-30
EP2768533A4 (en) 2015-03-11
AU2012326170A1 (en) 2014-04-24
JP6113176B2 (ja) 2017-04-12
CA2851639C (en) 2020-12-29
HK1200851A1 (en) 2015-08-14
US10293049B2 (en) 2019-05-21
US9393305B2 (en) 2016-07-19
HUE045624T2 (hu) 2020-01-28
TW201325610A (zh) 2013-07-01
JP2014530864A (ja) 2014-11-20
SG11201401563SA (en) 2014-09-26
JP2014530254A (ja) 2014-11-17
US20190314498A1 (en) 2019-10-17
US20160199489A1 (en) 2016-07-14
JP6220789B2 (ja) 2017-10-25
US20190216930A1 (en) 2019-07-18
TWI595883B (zh) 2017-08-21
US11129876B2 (en) 2021-09-28
CN103998060B (zh) 2016-12-21
CN104010654A (zh) 2014-08-27
JP2014530863A (ja) 2014-11-20
JP6110393B2 (ja) 2017-04-05
KR102163150B1 (ko) 2020-10-08
MX2014004725A (es) 2015-02-05
US20130108632A1 (en) 2013-05-02
BR112014009131A2 (pt) 2017-06-13
US20180193463A1 (en) 2018-07-12
AR088379A1 (es) 2014-05-28
EA201490803A1 (ru) 2014-09-30
AU2012326080B2 (en) 2017-02-16
US20180028668A1 (en) 2018-02-01
WO2013059410A1 (en) 2013-04-25
JP6220788B2 (ja) 2017-10-25
US20190314499A1 (en) 2019-10-17
US20190328875A1 (en) 2019-10-31
WO2013059405A1 (en) 2013-04-25
CA2851635A1 (en) 2013-04-25
EA026410B1 (ru) 2017-04-28
CA2851646A1 (en) 2013-04-25
EP2768525A4 (en) 2015-07-15
US20190314500A1 (en) 2019-10-17
AR088383A1 (es) 2014-05-28
US20190290767A1 (en) 2019-09-26
PL2768525T3 (pl) 2019-10-31
TW201325606A (zh) 2013-07-01
EA201490817A1 (ru) 2014-09-30
SG11201401576WA (en) 2014-10-30
BR112014009087A2 (pt) 2017-04-18
KR20140091707A (ko) 2014-07-22
AU2012326170B2 (en) 2016-12-22
AU2012326084A1 (en) 2014-04-17
TW201325609A (zh) 2013-07-01
CN104010654B (zh) 2017-10-27
CN104011073A (zh) 2014-08-27
EA028520B1 (ru) 2017-11-30
LT2768525T (lt) 2019-09-25
HK1200719A1 (en) 2015-08-14
IN2014CN02591A (OSRAM) 2015-06-26
CA2851639A1 (en) 2013-04-25
EP2768531A4 (en) 2015-03-11
US10772963B2 (en) 2020-09-15
EP2768854A4 (en) 2015-03-11
KR20140091706A (ko) 2014-07-22
MX2014004732A (es) 2015-05-15
MX2014004733A (es) 2015-05-15
WO2013059408A1 (en) 2013-04-25
US20130101640A1 (en) 2013-04-25
PT2768525T (pt) 2019-07-17
IL231826A0 (en) 2014-05-28
US9302002B2 (en) 2016-04-05
AR088460A1 (es) 2014-06-11
CN104011073B (zh) 2017-08-25
HK1200720A1 (en) 2015-08-14
WO2013059406A1 (en) 2013-04-25
MX2014004728A (es) 2015-05-15
US10376588B2 (en) 2019-08-13
US20200405865A1 (en) 2020-12-31
CN104010658A (zh) 2014-08-27
US20190184017A1 (en) 2019-06-20
EP2768535A1 (en) 2014-08-27
JP6104922B2 (ja) 2017-03-29
CN104010657A (zh) 2014-08-27
EA027325B1 (ru) 2017-07-31
CN103998061A (zh) 2014-08-20
IL231828A0 (en) 2014-05-28
BR112014009146A8 (pt) 2017-06-20
AR088380A1 (es) 2014-05-28
KR102068462B1 (ko) 2020-01-22
SI2768525T1 (sl) 2019-10-30
EP2768532A4 (en) 2015-03-11
US20190290766A1 (en) 2019-09-26
US20130101584A1 (en) 2013-04-25
SG11201401562RA (en) 2014-09-26
BR112014009031A2 (pt) 2017-05-09
SG11201401519RA (en) 2014-07-30
AU2012326082A1 (en) 2014-04-24
AR088381A1 (es) 2014-05-28
JP2014530862A (ja) 2014-11-20
IL231824A0 (en) 2014-05-28
AU2012326168B2 (en) 2016-12-15
MX367054B (es) 2019-08-02
KR20140091705A (ko) 2014-07-22
HK1200718A1 (en) 2015-08-14
US20190290765A1 (en) 2019-09-26
TWI619504B (zh) 2018-04-01
JP2014530255A (ja) 2014-11-17
BR112014009022A2 (pt) 2017-05-02
BR112014009131A8 (pt) 2017-06-20
US20190298837A1 (en) 2019-10-03
EA201490815A1 (ru) 2014-09-30
US20160317667A1 (en) 2016-11-03
AU2012326080A1 (en) 2014-04-24
US10980884B2 (en) 2021-04-20
ES2734070T3 (es) 2019-12-04
IN2014CN02592A (OSRAM) 2015-09-04
US10888619B2 (en) 2021-01-12
US20180125982A1 (en) 2018-05-10
AU2012326171A1 (en) 2014-04-24
US10980885B2 (en) 2021-04-20
CN103998060A (zh) 2014-08-20
MX2014004734A (es) 2015-05-15
US10213508B2 (en) 2019-02-26
US20130108633A1 (en) 2013-05-02
IL231829A0 (en) 2014-05-28
EP2768535A4 (en) 2015-03-11
RS59179B1 (sr) 2019-10-31

Similar Documents

Publication Publication Date Title
IN2014CN02527A (OSRAM)
WO2014039903A3 (en) Stable aqueous formulations of adalimumab
IN2015KN00005A (OSRAM)
TN2012000465A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
EA201390145A1 (ru) Конъюгаты, частицы, композиции и связанные с ними способы
AU2016204248A1 (en) Boron-Containing Molecules
EP4285928A3 (en) Anti-pdl1 antibody formulations
HK1205751A1 (en) Conjugates, particles, compositions, and related methods
EP2670397A1 (en) Pharmaceutical formulations including an amine compound
MX341324B (es) Polipeptidos.
PH12013501136A1 (en) Lysophosphatidic acid receptor antagonists and uses thereof
MY163083A (en) Solid forms of a pharmaceutically active substance
EA201391285A1 (ru) Производные тетрагидрохинолина, полезные в качестве ингибиторов бромодомена
PH12014501991B1 (en) Phenicol antibacterials
BR112015029462A2 (pt) Inibidores de quinase
IN2015DN04074A (OSRAM)
IN2015DN02109A (OSRAM)
PH12013502597A1 (en) Pyrazole derivatives useful as aldosterone synthase inhibitors
MX2014004742A (es) Nuevos agentes antibacterianos de fenicol.
PH12014500432A1 (en) Stable compositions and methods for preparing the same
TN2013000456A1 (en) Pyrazole derivatives useful as aldosterone synthase inhibitors
UA110829C2 (uk) Похідні піразолу, придатні як інгібітори альдостеронсинтази